Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Cardiale sarcoïdose Multi-center prospectief cohort (CHASM-CS)

30 oktober 2026 bijgewerkt door: Ottawa Heart Institute Research Corporation

Cardiale sarcoïdose Multi-center prospectieve cohortstudie

Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity.

There are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology/American Heart Association/Heart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS.

A multi-center collaborative approach to study CS is greatly needed." The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.

Studie Overzicht

Toestand

Werving

Gedetailleerde beschrijving

Baseline assessment of Clinically Manifest CS patients consists of: history, echocardiogram, ECG, chest CT scan, FDG-PET scan, blood for biomarkers within 2 months of the PET scan, cardiac MRI and possibly a signal average ECG and biopsy (encouraged-either endomyocardial or extra-cardiac).

Follow-up and clinical management of clinically manifest patients diagnosed with CS will occur at 3-6 months with a repeat FDG-PET scan and blood biomarkers. Follow-up will then be annually with an echo and ECG. Treatment with steroids/immunosuppressants and device therapy will be at the discretion of the treating physician.

Baseline assessment of patients diagnosed with extra-cardiac sarcoidosis and being screened for CS consists of: history, echocardiogram, ECG, holter, chest CT scan, biopsy, and cardiac MRI (CMR). If the CMR is suggestive of CS the patient will be have a FDG-PET scan done and be followed as a Clinically Silent patient. They will be contacted every 2 years. If the CMR is negative the patient will be followed as a extra-cardiac sarcoidosis patient with no evidence of CS and be in the control group. They will be contacted at 5 years and at the time of study completion.

All patients will be followed until the last patient recruited has been followed for 4 years.

The occurrence of the primary and secondary outcomes will be assessed in treated and untreated patients.

There will be 2 imaging core labs. The PET core lab will be located at UOHI under the direction of Dr. Robert Beanlands. The CMR core lab will be under the direction of Dr. Mathias Friedrich (McGill University). All scans will be read in the core labs by physicians who are blinded to the clinical details of the patients.

The Biomarker core lab will be at The University of Ottawa Heart Institute under the leadership of Dr P Liu.

Studietype

Observationeel

Inschrijving (Geschat)

1500

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Alberta
      • Calgary, Alberta, Canada, T2N 2T9
        • Werving
        • Libin Cardiovascular Institute of Alberta
        • Hoofdonderzoeker:
          • Russell Quinn, MD
        • Contact:
          • Russell Quinn, MD
      • Edmonton, Alberta, Canada, T6G 2B7
        • Werving
        • University of Alberta Hospital
        • Contact:
          • Tomascz Hruczkowski, MD
        • Hoofdonderzoeker:
          • Tomascz Hruczkowski, MD
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 1M9
        • Werving
        • St. Paul's Hospital
        • Contact:
          • Shanta Chakrabarti, MD
        • Hoofdonderzoeker:
          • Shanta Chakrabarti, MD
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 3A7
        • Werving
        • QEII Health Sciences Center
        • Hoofdonderzoeker:
          • Ciorsti MacIntyre, MD
        • Contact:
          • Kim Anderson, MD
    • Ontario
      • Hamilton, Ontario, Canada, L8L 2X2
        • Werving
        • Hamilton Health Sciences Centre
        • Hoofdonderzoeker:
          • Jeff Healey, MD
        • Contact:
          • Gerard Cox, MD
        • Contact:
          • Jeff Healey, MD
      • London, Ontario, Canada, N6A 5A5
        • Werving
        • London Health Sciences Centre
        • Contact:
          • Lorne Gula, MD
        • Hoofdonderzoeker:
          • Lorne Gula, MD
      • Newmarket, Ontario, Canada, L3Y 2P9
        • Werving
        • Southlake Regional Health Centre
        • Contact:
          • Bernice Tsang, MD
        • Hoofdonderzoeker:
          • Bernice Tsang, MD
      • Ottawa, Ontario, Canada, K1Y 4W7
        • Werving
        • University of Ottawa Heart Institute
        • Contact:
        • Hoofdonderzoeker:
          • David Birnie, MD
        • Contact:
      • Toronto, Ontario, Canada, M5G 2C4
        • Werving
        • Toronto General Hospital
        • Contact:
          • Andrew Ha, MD
        • Hoofdonderzoeker:
          • Andrew Ha, MD
    • Quebec
      • Montreal, Quebec, Canada, H1T 1C8
        • Werving
        • Montreal Heart Institute
        • Contact:
          • Lena Rivard, MD
        • Hoofdonderzoeker:
          • Lena Rivard, MD
      • Montreal, Quebec, Canada, H3G 1A4
        • Werving
        • McGill University Health Centre
        • Contact:
          • Fiorella Rafti
        • Hoofdonderzoeker:
          • Martin L Bernier, MD
      • Montreal, Quebec, Canada, H2W 1T8
        • Nog niet aan het werven
        • Centre Hospitalier de l"Universite de Montreal-Hotel Dieu
        • Contact:
          • Julie Fleury, RN
        • Hoofdonderzoeker:
          • Benoit Coutu, MD
    • Saskatchewan
      • Regina, Saskatchewan, Canada, S4P 0W5
        • Werving
        • Prairie Vascular Research Inc-Regina General Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Andrea Lavoie, MD
      • Sapporo, Japan, 060-8638
        • Werving
        • Hokkaido University
        • Contact:
        • Hoofdonderzoeker:
          • Ichizo Tsujino, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 99 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Kanssteekproef

Studie Bevolking

Electrophysiology Service patients

Beschrijving

Inclusion Criteria:

To diagnose Clinically Manifest CS all following criteria must be met:

(i) Positive biopsy* for Sarcoid (either EMB or extra-cardiac) AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis AND (iii) one or more of the following clinical features:

  • advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
  • non- sustained or sustained ventricular arrhythmia
  • ventricular dysfunction (LVEF < 50% and/or RVEF < 40%) AND (iv) No alternative explanation for clinical features AND (v) FDG-PET suggestive of active CS

To diagnose clinically silent CS all of the following criteria must be met

(i) Biopsy proven extra-cardiac sarcoidosis

AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis

AND (iii) CMR suggestive of cardiac sarcoidosis

AND (iv) Does not have criteria for clinically manifest CS ie. should not have any of following

  • advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
  • non- sustained or sustained ventricular arrhythmia
  • ventricular dysfunction (LVEF < 50% and/or RVEF < 40%)

Patients with negative CMR will be designated as 'extra-cardiac sarcoidosis with no evidence of CS' and followed as control

Exclusion Criteria:

  • unable or unwilling to provide informed consent
  • patients who are pregnant or lactating
  • patients with known claustrophobia
  • age < 18 years

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
CS screened as underlying etiology
  1. Patients with active Clinically Manifest CS
  2. Patients diagnosed with extra-cardiac sarcoidosis and being screened for CS

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Primary Outcome for ALL Patients
Tijdsspanne: Through study completion, on average 10 years

The primary outcome is a composite of cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation.

Heart failure hospitalization is defined as admission to hospital > 24 hours and received treatment for heart failure.

Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Secondary Outcomes for ALL Patients
Tijdsspanne: Through study completion, on average 10 years

1. Total mortality Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for ALL Patients
Tijdsspanne: Through study completion, on average 10 years

2. Individual components of primary outcome (cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tijdsspanne: Through study completion, on average 10 years

1. Change in LVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tijdsspanne: Through study completion, on average 10 years

2. Change in RVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tijdsspanne: Through study completion, on average 10 years

3. Change in cardiac disease activity from pre-treatment to on treatment and post-treatment cessation as assessed by FDG-PET Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tijdsspanne: Through study completion, on average 10 years

4. Atrial fibrillation burden (from ICD and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tijdsspanne: Through study completion, on average 10 years

5. Ventricular arrhythmia burden, including PVC burden (from ICD diagnostics and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tijdsspanne: Through study completion, on average 10 years

6. Appropriate ICD therapy Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tijdsspanne: Through study completion, on average 10 years

7. Percentage (%) of ventricular pacing Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Tijdsspanne: Through study completion, on average 10 years

8. AV nodal function Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Silent Disease and Control Patients
Tijdsspanne: Through study completion, on average 10 years

1. Development of Clinically Manifest CS Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Pablo Nery, MD, Ottawa Heart Institute Research Corporation
  • Hoofdonderzoeker: Rob Beanlands, MD, Ottawa Heart Institute Research Corporation
  • Hoofdonderzoeker: David Birnie, MD, Ottawa Heart Institute Research Corporation

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 augustus 2012

Primaire voltooiing (Geschat)

1 maart 2027

Studie voltooiing (Geschat)

1 december 2035

Studieregistratiedata

Eerst ingediend

10 november 2011

Eerst ingediend dat voldeed aan de QC-criteria

18 november 2011

Eerst geplaatst (Geschat)

22 november 2011

Updates van studierecords

Laatste update geplaatst (Werkelijk)

4 november 2026

Laatste update ingediend die voldeed aan QC-criteria

30 oktober 2026

Laatst geverifieerd

1 juni 2026

Meer informatie

Termen gerelateerd aan deze studie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren